Burrage Capital Management

What is Burrage Capital Management?

Burrage Capital Management is a long-short equity fund with a focus on the healthcare sector. Established in 2011 and based in Boston, Massachusetts, the firm commenced operations with the backing of its flagship investor, Foxconn Technologies. Burrage Capital implements a comprehensive investment strategy that revolves around meticulous medical and industry research.

Their primary objective is to pinpoint undervalued companies that exhibit potential in developing groundbreaking drugs, medical technologies, research tools, and diagnostics. In pursuit of transformative healthcare solutions, they create and invest in biotech companies that employ innovative technologies aimed at developing lifesaving drugs for patients.

Burrage Capital's involvement spans investing in both private and public companies, which grants them a unique longitudinal perspective on drug development across the industry. With over 30 years of experience in biotech investing and participation in the founding of over 40 companies since 2010, Burrage Capital has significantly contributed to the approval of 59 FDA-approved drugs.

Some of their noteworthy ventures include the founding of Orna Therapeutics, designed to outperform existing mRNA with cutting-edge circular RNA technology; Aktis Oncology, which advances the use of alpha radiopharmaceuticals for solid tumors; ElevateBio, which combines manufacturing, technologies, and therapeutic development; and NextPoint Therapeutics, targeting a new axis in cancer biology.

Burrage Capital's investment team comprises professionals specializing in research, drug development, company creation, corporate strategy, and commercialization. The team includes Entrepreneur Partners who bring extensive investor-operator expertise and collaborate with scientists and professionals to develop treatments for diseases with significant unmet medical needs.

Their portfolio companies are marked by strategic collaborations, executive role appointments, and financing rounds that testify to Burrage Capital's active role in steering these entities towards addressing critical challenges in healthcare.